Background Although new androgen-targeted therapies offer prolonged survival in
metastatic castration-resistant prostate cancer (CRPC), most men still face progressive …

For approximately a decade, chemotherapy has been shown to prolong life in patients with
metastatic castration-resistant prostate cancer (mCRPC). Since that time, however, only two …

The combination of cisplatin or carboplatin and etoposide is the standard treatment for
certain poorly differentiated neuroendocrine cancers, such as small-cell lung cancer. The …

Purpose With the emergence of various novel therapies including new generation taxane
and androgen-targeted therapies, the optimal sequence of systemic treatment in metastatic …

Background: The aim of the present study was to examine the efficacy of carboplatin in
combination with paclitaxel in patients with metastatic castration-resistant prostate cancer …

Background There are no effective chemotherapies for patients with metastatic castration-
resistant prostate cancer (mCRPC) whose disease has failed to respond to taxanes or …

Introduction: Prostate cancer is the second most common cause of cancer worldwide and is
the most frequently detected cancer in the European Union in men over 50 years of age …

5148 Background: Docetaxel has a survival benefit in CRPC. Oral and IV platinum
derivatives have activity in CRPC. We hypothesized that a novel combination of docetaxel …

Chemotherapy for men with metastatic castration-resistant prostate cancer (CRPC)
conferred no survival advantage until 2004 when docetaxel was shown to improve survival …

Aims: Carboplatin plus etoposide has modest efficacy in docetaxel-pretreated castration-
resistant prostate cancer patients. We hypothesized that carboplatin–etoposide could still …